That increase was more than threefold in the ER positive subgroup, suggesting that longer treatment with dual anti HER-2 therapy in combination with endocrine therapy, and without chemotherapy, leads to a meaningful increase in pCR rate in ER+/HER-2+ breast cancer and warrants further study. Here, ESR1 is linked to breast carcinoma.